These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19382183)

  • 1. Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial.
    Friedman ES; Wisniewski SR; Gilmer W; Nierenberg AA; Rush AJ; Fava M; Zisook S; Balasubramani GK; Trivedi MH
    Depress Anxiety; 2009; 26(7):612-21. PubMed ID: 19382183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    Trivedi MH; Rush AJ; Wisniewski SR; Nierenberg AA; Warden D; Ritz L; Norquist G; Howland RH; Lebowitz B; McGrath PJ; Shores-Wilson K; Biggs MM; Balasubramani GK; Fava M;
    Am J Psychiatry; 2006 Jan; 163(1):28-40. PubMed ID: 16390886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report.
    Gilmer WS; Gollan JK; Wisniewski SR; Howland RH; Trivedi MH; Miyahara S; Fleck J; Thase ME; Alpert JE; Nierenberg AA; Warden D; Fava M; Rush AJ
    J Clin Psychiatry; 2008 Aug; 69(8):1246-56. PubMed ID: 18681756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study.
    Zisook S; Trivedi MH; Warden D; Lebowitz B; Thase ME; Stewart JW; Moutier C; Fava M; Wisniewski SR; Luther J; Rush AJ
    J Affect Disord; 2009 Sep; 117(1-2):63-73. PubMed ID: 19217668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report.
    Warden D; Trivedi MH; Wisniewski SR; Davis L; Nierenberg AA; Gaynes BN; Zisook S; Hollon SD; Balasubramani GK; Howland R; Fava M; Stewart JW; Rush AJ
    Am J Psychiatry; 2007 Aug; 164(8):1189-97. PubMed ID: 17671281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Income and attrition in the treatment of depression: a STAR*D report.
    Warden D; Rush AJ; Wisniewski SR; Lesser IM; Thase ME; Balasubramani GK; Shores-Wilson K; Nierenberg AA; Trivedi MH
    Depress Anxiety; 2009; 26(7):622-33. PubMed ID: 19582825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic subgroups for citalopram response in the STAR*D trial.
    Jakubovski E; Bloch MH
    J Clin Psychiatry; 2014 Jul; 75(7):738-47. PubMed ID: 24912106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes.
    Davis LL; Wisniewski SR; Howland RH; Trivedi MH; Husain MM; Fava M; McGrath PJ; Balasubramani GK; Warden D; Rush AJ
    Drug Alcohol Depend; 2010 Mar; 107(2-3):161-70. PubMed ID: 19945804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.
    Fava M; Rush AJ; Alpert JE; Balasubramani GK; Wisniewski SR; Carmin CN; Biggs MM; Zisook S; Leuchter A; Howland R; Warden D; Trivedi MH
    Am J Psychiatry; 2008 Mar; 165(3):342-51. PubMed ID: 18172020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D.
    Gaynes BN; Rush AJ; Trivedi MH; Wisniewski SR; Balasubramani GK; McGrath PJ; Thase ME; Klinkman M; Nierenberg AA; Yates WR; Fava M
    J Gen Intern Med; 2008 May; 23(5):551-60. PubMed ID: 18247097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report.
    Wisniewski SR; Rush AJ; Nierenberg AA; Gaynes BN; Warden D; Luther JF; McGrath PJ; Lavori PW; Thase ME; Fava M; Trivedi MH
    Am J Psychiatry; 2009 May; 166(5):599-607. PubMed ID: 19339358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and functional outcomes of patients who experience partial response to citalopram: secondary analysis of STAR*D.
    Dennehy EB; Marangell LB; Martinez J; Balasubramani GK; Wisniewski SR
    J Psychiatr Pract; 2014 May; 20(3):178-87. PubMed ID: 24847991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do atypical features affect outcome in depressed outpatients treated with citalopram?
    Stewart JW; McGrath PJ; Fava M; Wisniewski SR; Zisook S; Cook I; Nierenberg AA; Trivedi MH; Balasubramani GK; Warden D; Lesser I; John Rush A
    Int J Neuropsychopharmacol; 2010 Feb; 13(1):15-30. PubMed ID: 19341509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sexual satisfaction and quality of life in major depressive disorder before and after treatment with citalopram in the STAR*D study.
    Ishak WW; Christensen S; Sayer G; Ha K; Li N; Miller J; Nguyen JM; Cohen RM
    J Clin Psychiatry; 2013 Mar; 74(3):256-61. PubMed ID: 23561231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication augmentation after the failure of SSRIs for depression.
    Trivedi MH; Fava M; Wisniewski SR; Thase ME; Quitkin F; Warden D; Ritz L; Nierenberg AA; Lebowitz BD; Biggs MM; Luther JF; Shores-Wilson K; Rush AJ;
    N Engl J Med; 2006 Mar; 354(12):1243-52. PubMed ID: 16554526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study.
    Mrazek DA; Biernacka JM; McAlpine DE; Benitez J; Karpyak VM; Williams MD; Hall-Flavin DK; Netzel PJ; Passov V; Rohland BM; Shinozaki G; Hoberg AA; Snyder KA; Drews MS; Skime MK; Sagen JA; Schaid DJ; Weinshilboum R; Katzelnick DJ
    J Clin Psychopharmacol; 2014 Jun; 34(3):313-7. PubMed ID: 24743713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.
    Hu XZ; Rush AJ; Charney D; Wilson AF; Sorant AJ; Papanicolaou GJ; Fava M; Trivedi MH; Wisniewski SR; Laje G; Paddock S; McMahon FJ; Manji H; Lipsky RH
    Arch Gen Psychiatry; 2007 Jul; 64(7):783-92. PubMed ID: 17606812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of fatigue on outcome of selective serotonin reuptake inhibitor treatment: secondary analysis of STAR*D.
    Ferguson M; Dennehy EB; Marangell LB; Martinez J; Wisniewski SR
    Curr Med Res Opin; 2014 Oct; 30(10):2109-18. PubMed ID: 24949937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.